Alnylam Pharmaceuticals Inc ALNY

NASDAQ US Biotechnology

$205.52 ▲ +0.02% (+$0.04)

📉 Near 52W Low

Open $205.46

Prev Close $205.48

Day Range $200.11 – $207.99

52W Range $197.81 – $495.55

Market Cap $43.19B

P/E (TTM) 47.67

Beta 0.26

EPS (TTM) $4.18

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2004-05-28
Shares Out.	133,510,000
Website	alnylam.com/ ↗
Phone	13026587581
Employees	2,500
Revenue	$1.17B
Gross Profit	$959.7M
Net Income	$206.0M
Free Cash Flow	$641.3M
Total Assets	$5.13B
Total Liabilities	$4.05B
Equity	$1.08B

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Alnylam Pharmaceuticals Inc is a publicly traded company under the ticker symbol ALNY on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.